On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Exclusion Criteria

• •1. Received other chimeric antigen receptor therapy or gene modified cell therapy before screening;
• •2. Subjects who were undergoing systemic steroid therapy during screening and were determined by the researchers to require long-term use of systemic steroid therapy during the treatment period (excluding inhalation or local use);
• •3. Any unstable heart disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III), and severe arrhythmia.